Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

WZB117

SKU: orb1226756

Description

WZB117 (WZB-117) is a small-molecule inhibitor of glucose transporter 1 (GLUT1), inhibits glucose transport and cancer cell proliferation with IC50 of 10 uM; decreases in levels of Glut1 protein, intracellular ATP, and glycolytic enzymes in treated cancer cells, inhibits cancer growth in tumor-bearing nude mice; also inhibits the self-renewal and tumor-initiating capacity of cancer stem cells (CSCs).

Images & Validation

Key Properties

CAS Number1223397-11-2
MW368.316
Purity>98% (HPLC)
FormulaC20H13FO6
SMILESFC1=C(OC(C2=CC=CC(O)=C2)=O)C(OC(C3=CC=CC(O)=C3)=O)=CC=C1
TargetGLUT
SolubilityDMSO: 36.8 mg/mL (100 mM); Ethanol: 36.8 mg/mL (100 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble )

Bioactivity

In Vivo
The animal study shows that after daily intraperitoneal injection of WZB117 at 10 mg/kg body weight, the sizes of the compound-treated tumors are on average more than 70% smaller than those of the mock (PBS/DMSO)-treated tumors. Notably, 2 of the 10 compound-treated tumors disappear during the treatment and never grow back even at the end of the study. Body weight measurement and analysis reveal that the mice treated with WZB117 lost about 1 to 2 grams of body weight compared with the mock-treated mice with most of the weight loss in the fat tissue. Blood counts and analysis of mice at the end of the study show that lymphocytes and platelets are changed in the compound-treated mice compared with the vehicle-treated mice, but the cell counts remained in the normal ranges. One of the concerns for using glucose transport inhibitors is that the inhibitor might produce hyperglycemia in the treated mice.
In Vitro
Glucose uptake assays show that WZB117 inhibits glucose transport in cancer cells in a dose-dependent manner. The inhibition of glucose transport induced by WZB117 occurres within 1 minute after the assay started, suggesting that the inhibitory activity is likely to be via a direct and fast mechanism. Cell viability assay shows that WZB117 inhibits cancer cell proliferation with an IC50 of approximately 10 μM. The inhibitory activity of WZB117 on cancer cell growth is also confirmed with a clonogenic assay, which also indicates that the inhibition is irreversible in nature. WZB117 treatment results in significantly more cell growth inhibition in lung cancer A549 cells than in nontumorigenic lung NL20 cells. Similar results are also observed in breast cancer MCF7 cells and their nontumorigenic MCF12A cells. When WZB117 is added to cancer cells grown under hypoxic conditions, more cell growth inhibition is observed than under normoxic conditions.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

WZB-117

Similar Products

  • WZB117 [orb1300139]

    >98%

    1223397-11-2

    368.3

    C20H13FO6

    5 mg, 25 mg
  • WZB117-PPG [orb3133556]

    C50H43FN2O14

    50 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

5 mg
$ 90.00
10 mg
$ 130.00
25 mg
$ 240.00
50 mg
$ 380.00
100 mg
$ 550.00
200 mg
$ 810.00
500 mg
$ 1,290.00